Goldman Sachs Downgrades Emerson (EMR) to Neutral Citing Lack of Catalysts
Tweet
Share
E-mailGet Alerts EMR Hot Sheet
Price: $157.26 +1.64%
Rating Summary:
26 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
26 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Goldman Sachs downgraded Emerson (NYSE: EMR) from Buy to Neutral with a price target of $54 citing a lack of near-term catalysts.
Despite an above-average dividend yield, strong free cash flow, low sentiment and 2011 underperformance, "EMR shares may struggle to outperform until a resumption of estimate revision momentum re-emerges, which could take several quarters."
For an analyst ratings summary and ratings history on Emerson click here. For more ratings news on Emerson click here.
Shares of Emerson closed at $48.70 yesterday.
Despite an above-average dividend yield, strong free cash flow, low sentiment and 2011 underperformance, "EMR shares may struggle to outperform until a resumption of estimate revision momentum re-emerges, which could take several quarters."
For an analyst ratings summary and ratings history on Emerson click here. For more ratings news on Emerson click here.
Shares of Emerson closed at $48.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Shanghai Jahwa United (600315:CH) to Neutral
- Deutsche Bank Downgrades Straumann Holding AG (STMN:SW) (SAUHF) to Hold
- Kepler Cheuvreux Downgrades Avantium N.V (AVTX:NA) to Reduce
Create E-mail Alert Related Categories
DowngradesRelated Entities
Goldman Sachs, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
